XBIT

XBiotech Inc. [XBIT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XBIT Stock Summary

Top 10 Correlated Stocks

XBIT

In the News

XBIT Financial details

Company Rating
-
Market Cap
281.54M
Income
-24.56M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-5.99
Forward P/E
-
PEG
2.4
P/S
461.63
P/B
0.62
P/C
-
P/FCF
-10.68
Quick Ratio
38.44
Current Ratio
38.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-57.14%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
-10%
ROC
-0.17%
Gross Margin
95%
Oper. Margin
-12362%
Profit Margin
-7708%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.05-9.96
52W High
-66.22%
52W Low
+1.33%
RSI
45
Rel Volume
1.12
Avg Volume
65.32K
Volume
73.39K
Perf Week
-2.56%
Perf Month
-12.64%
Perf Quarter
-59.25%
Perf Half Y
-60.57%
-
-
-
-
Beta
1.487
-
-
Volatility
0.1%, 0.18%
Prev Close
5.92%
Price
3.04
Change
7.23%

Something similar

Top by Market Cap
3V64.DE
MSFT
MSF.DE
DHR-PB
NVD.DE
Same Sector
PBSV
KOO.L
AGLE
0QLN.L
TARS
Top Correlated Stocks
NAUT
000679.SZ
RMBL
XFOR
MNDO
Similar Market Cap
0NES.L
GROY
ZUMZ
0608.HK
M7U.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 65.32K
  • Market Capitalization 281.54M
  • Employee 82
  • CEO Mr. John Simard
  • Headquarters Austin,TX,US
  • IPO Date 2015-04-15
  • Website https://www.xbiotech.com

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.